ARS Pharmaceuticals, Inc. (SPRY) Free cash flow 2020–2025
ARS Pharmaceuticals, Inc. (SPRY) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$171.2MFY2025 · since FY2020: -$32.1M → -$171.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$171.2M | -1418.5% |
| FY2024 | $13.0M | +121.8% |
| FY2023 | -$59.4M | -47.6% |
| FY2022 | -$40.3M | -128.6% |
| FY2021 | -$17.6M | +45.1% |
| FY2020 | -$32.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice